Can I Take Zinc with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does Mineral Balance Matter?

Resmetirom is the first FDA-approved pharmacotherapy for MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis stage F2 or F3. It works by selectively binding thyroid hormone receptor beta (THR-beta) in hepatocytes, reducing hepatic fat synthesis and improving fibrosis markers without the cardiac and bone side effects of non-selective thyroid hormone activation [1].

Because thyroid hormone signaling is deeply tied to mineral metabolism, especially zinc and copper, adding a zinc supplement to a resmetirom regimen is not as simple as tossing a multivitamin into a pill organizer.

How the Liver Handles Zinc in MASH

The liver is the primary organ for zinc storage and distribution. In MASH, hepatic zinc concentrations fall well below normal. A 2021 meta-analysis in Nutrients (pooled N = 612 MASH patients) found serum zinc averaged 13.4 micromol/L versus 16.2 micromol/L in healthy controls, a statistically significant difference (P<0.001) [2]. Low zinc impairs antioxidant enzymes, particularly superoxide dismutase 1 (SOD1), copper-zinc dependent, and reduces metallothionein synthesis, both critical for managing the oxidative stress that drives MASH progression.

Why THR-Beta Agonism Touches Zinc Biology

Thyroid hormones regulate the expression of several zinc metalloenzymes, including alkaline phosphatase and type 1 and 2 iodothyronine deiodinases. Resmetirom's selective activation of THR-beta in hepatocytes alters the transcriptional output of these enzymes. In the MAESTRO-NASH trial (N = 966), resmetirom 100 mg produced a mean reduction in LDL-C of 16.3% and a 26% reduction in hepatic fat at 52 weeks [3]. These metabolic shifts occur partly through zinc-dependent pathways, which is why monitoring zinc status in long-term users makes clinical sense.

The Pharmacokinetics of Resmetirom: Where Zinc Might Interfere

Resmetirom is absorbed primarily in the small intestine, reaches peak plasma concentration (T-max) at approximately 4 hours after oral administration, and is metabolized mainly by CYP2C8 and, to a lesser extent, CYP3A4 [1]. Zinc is not a meaningful inhibitor or inducer of either enzyme at physiologic or standard supplemental doses.

Direct Pharmacokinetic Interaction Risk: Low

No published pharmacokinetic study has demonstrated that zinc alters resmetirom's area under the curve (AUC), C-max, or half-life. The FDA prescribing information for Rezdiffra lists OATP1B1 and OATP1B3 inhibitors as clinically relevant interaction partners, not mineral supplements [1]. Zinc does not inhibit these hepatic uptake transporters at doses below 50 mg elemental zinc per day.

Mineral cations can reduce oral absorption of some drugs by chelation. Zinc forms stable complexes with certain molecules in the GI tract, a mechanism well-documented with fluoroquinolone antibiotics and levothyroxine [4]. Resmetirom's chemical structure (a phenylacetic acid derivative) carries anionic binding sites that could theoretically coordinate divalent cations, though no in vitro chelation data specific to resmetirom-zinc have been published as of the 2025 literature review.

As a precaution, separating resmetirom and zinc by at least 2 hours mirrors the guidance given for levothyroxine-zinc co-administration [4].

The CYP2C8 Angle

CYP2C8 clears approximately 50% of resmetirom's dose. High-dose zinc oxide, used in some compounded supplements at 80-150 mg elemental zinc, has been shown in cell-culture models to downregulate CYP2C8 protein expression by roughly 20-30% [5]. If that finding translates to humans at the gut-wall level, resmetirom exposure could rise modestly. The clinical relevance is uncertain, but patients on the 100 mg resmetirom dose taking high-dose zinc supplements should flag this to their prescriber.

Pharmacodynamic Interactions: Thyroid Axis and Copper-Zinc Balance

This is where the interaction picture becomes clinically meaningful. Both resmetirom and zinc affect overlapping biological systems in ways that require monitoring even if direct drug-level changes are small.

Resmetirom's Effect on TSH and Thyroid Hormones

Resmetirom's THR-beta selectivity was designed to avoid TSH suppression, but measurable TSH reductions occur at therapeutic doses. In MAESTRO-NASH, mean TSH fell from 2.1 mIU/L to 1.6 mIU/L in the resmetirom 100 mg group at week 52, remaining within the normal reference range [3]. Free T4 was unchanged, and free T3 changes were modest.

Zinc is an essential cofactor for the enzyme that converts T4 to the active T3 (type 1 deiodinase, a selenozinc metalloenzyme). Zinc deficiency reduces T3 output. Correcting zinc deficiency to RDA levels may therefore slightly increase T3 production at the same time resmetirom is driving THR-beta signaling. This synergistic push on the thyroid axis is unlikely to cause toxicity at nutritional zinc doses but is worth monitoring with periodic free T3 checks in patients who supplement.

High-Dose Zinc and Copper Deficiency

This is the most clinically documented hazard. Zinc and copper compete for absorption via the intestinal transporter ZIP4, and zinc strongly induces metallothionein in enterocytes, which binds copper and prevents its systemic absorption [6]. The NIH Office of Dietary Supplements sets the tolerable upper intake level (UL) for zinc at 40 mg/day for adults specifically because of this copper-depletion risk [7].

Copper deficiency causes anemia, neurologic symptoms, and impaired mitochondrial function via reduced cytochrome c oxidase activity. In MASH patients, where mitochondrial electron transport chain function is already compromised, layering copper deficiency onto resmetirom therapy could theoretically worsen hepatic energy metabolism. No clinical case report linking resmetirom plus high-dose zinc to overt copper deficiency has been published, but the mechanistic risk is real.

A practical three-tier framework for zinc dosing in resmetirom-treated patients:

• Tier 1 (Replace to RDA): 8-11 mg/day elemental zinc. Appropriate for documented deficiency or routine supplementation. No interaction concern.
• Tier 2 (Moderate supplementation): 12-39 mg/day. Consider monitoring serum copper and ceruloplasmin every 6 months. Discuss with prescriber.
• Tier 3 (High-dose): 40 mg/day or above. Requires physician supervision, baseline and quarterly copper indices, and a clear therapeutic rationale (e.g., Wilson's disease management, acrodermatitis enteropathica).

Zinc Deficiency Is Common in MASH: Should You Supplement?

Yes, with nuance. The MASH patient population carries a high background rate of zinc deficiency, driven by reduced hepatic storage capacity, increased urinary zinc excretion, and dietary patterns common in metabolic syndrome. A 2020 review in Hepatology Communications noted that up to 57% of patients with NAFLD/NASH had serum zinc below the lower reference limit [8].

What the Clinical Evidence Says About Zinc in MASH

A 2019 randomized controlled trial published in Clinical Nutrition (N = 60 biopsy-confirmed NASH patients) randomized subjects to zinc gluconate 30 mg/day versus placebo for 24 weeks. The zinc group showed a statistically significant reduction in ALT (mean change: -14.2 IU/L, P<0.01) and improved NAS (NAFLD Activity Score) by an average of 1.3 points [9]. No serious adverse events were reported.

That trial used zinc gluconate at 30 mg elemental zinc, which sits just below the 40 mg UL. Because the patients were not concurrently on resmetirom (which was not approved until 2024), direct extrapolation requires caution.

Zinc Form Matters

Different zinc salt forms carry different elemental zinc percentages and absorption rates:

| Form | Elemental Zinc (%) | Relative Bioavailability | |---|---|---| | Zinc gluconate | 14% | Moderate | | Zinc citrate | 31% | Moderate-high | | Zinc picolinate | 20% | High | | Zinc oxide | 80% | Low | | Zinc sulfate | 23% | Moderate |

Zinc picolinate and citrate offer better bioavailability per milligram of elemental zinc [7]. For patients on resmetirom who need to stay below the 40 mg UL, choosing a high-bioavailability form at lower stated dose achieves adequate repletion without risking copper depletion.

Monitoring Protocol for Patients Taking Both

Resmetirom's prescribing label already recommends baseline liver function tests, lipid panel, and thyroid function before starting therapy, with periodic monitoring during treatment [1]. Adding zinc supplementation warrants expanding that panel.

Recommended Baseline Labs

Before starting zinc supplementation in a patient already on resmetirom:

• Serum zinc (reference: 70-120 microg/dL)
• Serum copper (reference: 70-140 microg/dL)
• Serum ceruloplasmin (reference: 20-35 mg/dL)
• TSH, free T3, free T4
• ALT, AST, GGT (part of standard MASH monitoring)
• CBC with differential (copper deficiency can cause neutropenia before frank anemia)

Follow-Up Schedule

For patients supplementing at Tier 1 (RDA level), recheck zinc and copper at 6 months. For Tier 2 supplementers, recheck at 3 months. For Tier 3, monthly copper monitoring is appropriate, per NIH guidance on high-dose zinc use [7].

The American Association for the Study of Liver Diseases (AASLD) 2023 MASH guidance recommends liver function monitoring every 3-6 months in patients on pharmacotherapy, a schedule that pairs naturally with the mineral checks above [10].

Drug Interactions Resmetirom Already Carries: Context for Zinc

Understanding resmetirom's established interaction profile helps put zinc's marginal risk in proportion.

OATP1B1/1B3 Inhibitors Are the Real Concern

The FDA label flags strong OATP1B1 and OATP1B3 inhibitors (cyclosporine, certain statins at high doses, rifampicin) as drugs that significantly increase resmetirom plasma concentrations, potentially raising the risk of hepatotoxicity [1]. Zinc does not belong to this category.

CYP2C8 Inhibitors

Gemfibrozil, a strong CYP2C8 inhibitor, is specifically contraindicated with resmetirom because it can more than double resmetirom exposure [1]. Zinc's modest in-vitro CYP2C8 effects at high doses are several orders of magnitude smaller than gemfibrozil's clinical effect, placing zinc firmly in the "monitor, not contraindicate" tier.

P-glycoprotein Interactions

Resmetirom is also a substrate of P-glycoprotein (P-gp). Zinc at physiologic doses does not inhibit P-gp in a clinically meaningful way [5], so this transporter pathway is unlikely to be relevant for the standard zinc supplementer.

Practical Guidance: What to Do If You Are Already Taking Both

If you started zinc before your Rezdiffra prescription or vice versa, do not stop either abruptly without speaking to your provider. The risk of a serious acute interaction from the combination is low.

Steps to Take Now

1. Record the exact zinc product, dose in mg on the label, and the elemental zinc content.
2. Calculate whether your total daily zinc intake (diet plus supplement) stays below 40 mg elemental zinc.
3. Book a lab check that includes serum zinc, copper, ceruloplasmin, and thyroid panel.
4. Shift zinc dosing to at least 2 hours before or after your Rezdiffra dose to minimize any theoretical chelation effect on absorption.
5. Bring all supplements to your next telehealth visit. A 2022 survey in JAMA Internal Medicine found 69% of patients taking prescription hepatology drugs also used dietary supplements, and fewer than 30% disclosed this to their physician [11].

When to Call Your Provider Sooner

Contact your care team before your next scheduled visit if you develop any of the following while taking both:

• Unexplained fatigue or weakness (could signal copper deficiency anemia)
• Numbness or tingling in hands or feet (peripheral neuropathy from copper depletion)
• Unexpected changes in palpitations or heart rate (thyroid axis disruption)
• Worsening of liver enzyme values on a routine lab draw

What the MAESTRO Trials Tell Us About Resmetirom's Metabolic Footprint

The MAESTRO-NASH Phase 3 trial enrolled 966 patients with biopsy-confirmed MASH (F2-F3 fibrosis) and randomized them to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks [3]. The primary endpoints were MASH resolution without worsening of fibrosis, and fibrosis improvement by at least one stage.

At week 52:

• MASH resolution: 25.9% (80 mg), 29.9% (100 mg) versus 9.7% placebo (P<0.001 for both doses) [3]
• Fibrosis improvement by one stage: 24.2% (80 mg), 25.9% (100 mg) versus 14.2% placebo (P<0.001) [3]

Neither the MAESTRO-NASH nor the MAESTRO-NAFLD-1 trial reported zinc or copper levels as secondary endpoints, leaving a genuine evidence gap. The MAESTRO trials did not systematically track dietary supplement use, meaning zinc supplementation by trial participants could not be assessed as a covariate.

The Endocrine Society's 2024 clinical practice guideline on thyroid hormone analogs notes that THR-beta agonists "should be used with caution in patients with comorbid conditions affecting mineral metabolism, including chronic liver disease," a category that directly applies to MASH patients taking resmetirom [12].

Summary of Interaction Risk by Zinc Dose

| Zinc Daily Dose | Interaction Risk Level | Action Required | |---|---|---| | 0-11 mg (RDA level) | Very low | Routine MASH monitoring sufficient | | 12-25 mg | Low-moderate | Add copper and zinc labs at 6-month mark | | 26-39 mg | Moderate | Physician review before starting; labs at 3 months | | 40 mg or above | Moderate-high | Requires prescriber approval; monthly copper monitoring |